公开(公告)号：US20180106814A1

公开(公告)日：2018-04-19

申请号：US15809160

申请日：2017-11-10

申请人： SYSMEX CORPORATION ,  NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY ,  NAGOYA CITY UNIVERSITY ,  NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE

发明人： Hisashi Narimatsu ,  Yuzuru Ikehara ,  Atsushi Kuno ,  Maki Sogabe ,  Yasuhito Tanaka ,  Masashi Mizokami ,  Kiyoaki Ito ,  Shunsuke Matsubara ,  Chikayuki Tsuruno ,  Youichi Takahama ,  Takashi Kagawa ,  Shinya Nagai

IPC分类号： G01N33/68 ,  G01N33/574 ,  C07K14/47

CPC分类号： G01N33/68 ,  C07K14/4726 ,  C07K14/473 ,  G01N33/5308 ,  G01N33/57438 ,  G01N33/6893 ,  G01N2333/4724 ,  G01N2333/4728 ,  G01N2400/00 ,  G01N2400/02 ,  G01N2800/085 ,  Y10T436/143333

摘要： An object of the present invention is to provide a method for measuring a glycan-marker glycoprotein, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a method for examining liver disease, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a reagent for quantitative determination of a glycoprotein, which is used for the above measurement methods. Furthermore, an object of the present invention is to provide a glycan-marker glycoprotein as an index for clinical conditions of liver disease, which is capable of identifying the clinical conditions of liver disease depending on the progress of liver disease. The method for measuring a glycoprotein is characterized in that: the glycoprotein is at least one glycoprotein selected from alpha-1-acid glycoprotein (AGP) and Mac-2-binding protein (M2BP) contained in a sample collected from a subject; when the glycoprotein is AGP, AGP binding to a first lectin selected from AOL and MAL is measured; and when the glycoprotein is M2BP, M2BP binding to a second lectin selected from WFA, BPL, AAL, RCA120, and TJAII is measured.

公开(公告)号：US11840578B2

公开(公告)日：2023-12-12

申请号：US17332243

申请日：2021-05-27

申请人： SYSMEX CORPORATION

发明人： Youichi Takahama ,  Hideki Matsuzaki ,  Takuya Kyoutou

IPC分类号： C07K16/42 ,  C07K16/06 ,  C07K19/00 ,  G01N33/68 ,  G01N33/96

CPC分类号： C07K16/4283 ,  C07K16/065 ,  C07K19/00 ,  G01N33/6854 ,  G01N33/6893 ,  G01N33/96 ,  G01N2333/42 ,  G01N2333/4724 ,  G01N2800/347

摘要： Disclosed is a calibrator comprising IgA having a biotin group and a biotin-binding site, the calibrator being used to obtain a concentration of an IgA aggregate in a sample.

公开(公告)号：US20140057286A1

公开(公告)日：2014-02-27

申请号：US14051729

申请日：2013-10-11

申请人： Sysmex Corporation ,  National Center for Global Health and Medicine ,  Nagoya City University ,  National Institute of Advanced Industrial Science and Technology

发明人： Hisashi Narimatsu ,  Yuzuru Ikehara ,  Atsushi Kuno ,  Maki Sogabe ,  Yasuhito Tanaka ,  Masashi Mizokami ,  Kiyoaki Ito ,  Shunsuke Matsubara ,  Chikayuki Tsuruno ,  Youichi Takahama ,  Takashi Kagawa ,  Shinya Nagai

IPC分类号： G01N33/68

CPC分类号： G01N33/68 ,  C07K14/4726 ,  C07K14/473 ,  G01N33/5308 ,  G01N33/57438 ,  G01N33/6893 ,  G01N2333/4724 ,  G01N2333/4728 ,  G01N2400/00 ,  G01N2400/02 ,  G01N2800/085 ,  Y10T436/143333

摘要： An object of the present invention is to provide a method for measuring a glycan-marker glycoprotein, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a method for examining liver disease, by which liver disease can be detected with higher accuracy than is possible with conventional methods. Also, an object of the present invention is to provide a reagent for quantitative determination of a glycoprotein, which is used for the above measurement methods. Furthermore, an object of the present invention is to provide a glycan-marker glycoprotein as an index for clinical conditions of liver disease, which is capable of identifying the clinical conditions of liver disease depending on the progress of liver disease. The method for measuring a glycoprotein is characterized in that: the glycoprotein is at least one glycoprotein selected from alpha-1-acid glycoprotein (AGP) and Mac-2-binding protein (M2BP) contained in a sample collected from a subject; when the glycoprotein is AGP, AGP binding to a first lectin selected from AOL and MAL is measured; and when the glycoprotein is M2BP, M2BP binding to a second lectin selected from WFA, BPL, AAL, RCA120, and TJAII is measured.

摘要翻译： 本发明的目的是提供一种测定聚糖标记糖蛋白的方法，通过该方法可以以比常规方法更高的精度检测肝脏疾病。 另外，本发明的目的在于提供一种检查肝脏疾病的方法，通过该方法能够以比常规方法更高的精度检测肝脏疾病。 另外，本发明的目的在于提供一种用于上述测定方法的糖蛋白定量试剂。 此外，本发明的目的是提供聚糖标记糖蛋白作为肝病临床病症的指标，其能够根据肝病的进展来鉴定肝脏疾病的临床状况。 测定糖蛋白的方法的特征在于：糖蛋白是从受试者收集的样品中含有的至少一种糖蛋白，其选自α-1-酸糖蛋白（AGP）和Mac-2结合蛋白（M2BP） 当糖蛋白为AGP时，测量与选自AOL和MAL的第一凝集素结合的AGP; 并且当糖蛋白为M2BP时，测量与选自WFA，BPL，AAL，RCA120和TJAII的第二凝集素结合的M2BP。